Over the last twenty-five years, academic research has been one of the major driving forces behind the spectacular development of gene therapy for rare or acquired diseases.
Due to the success of recent clinical trials of the last generations of gene therapy products to treat rare genetic diseases and to favorable orphan drug legislation in both Europe and the United States, the biotechnology and pharmaceutical industry is now heavily investing in the field, giving hope to become standard clinical practice.
The Gene Therapy Area of Major Interest (DIM Gene Therapy) launches the first edition of Gene Therapy for Rare Monogenic Diseases, an international scientific symposium dedicated to recent knowledge and progress in the field to ensure faster and more efficacious development of therapies for diseases with high unmet medical needs. With 200 intended key actors, this two-day event is the unique opportunity to discover the latest gene therapy trends and to see emerge high-potential collaborations.
THE PROGRAM INCLUDES
- Conferences with international high-level speakers from Europe and the US, mainly focused on clinical gene therapy
- Presentations of research activities and major achievements from the Gene
Therapy Area of Major Interest initiative research teams in the larger context of the recent progress in the field
- Posters on the latest gene therapy trends and technologies
WHY PARTICIPATE ?
- Meet international key actors in the field of gene therapy
- Discover the latest trends in the field
- Get an overview of the most innovative ongoing research projects led by Paris Region academic groups under the Gene Therapy Area of Major Interest